Artivion (NYSE:AORT) Upgraded at Jefferies Financial Group

Artivion (NYSE:AORT) was upgraded by stock analysts at Jefferies Financial Group to a “strong-buy” rating in a note issued to investors on Tuesday, Zacks reports.

AORT has been the topic of a number of other research reports. Wall Street Zen lowered Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Canaccord Genuity Group boosted their price objective on Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Needham & Company LLC restated a “buy” rating and set a $44.00 target price on shares of Artivion in a research note on Monday, July 20th. Finally, Citigroup restated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $42.86.

Artivion Stock Up 3.8%

Shares of NYSE AORT opened at $23.12 on Tuesday. The stock has a market cap of $1.13 billion, a P/E ratio of 41.26 and a beta of 1.23. The business’s fifty day simple moving average is $24.69 and its 200-day simple moving average is $26.10. Artivion has a 12-month low of $19.16 and a 12-month high of $48.25. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82.

Artivion (NYSE:AORT) last released its earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. The firm had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. As a group, equities analysts predict that Artivion will post 0.45 EPS for the current fiscal year.

Insider Activity

In other news, SVP Andrew Green sold 11,480 shares of Artivion stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $24.97, for a total transaction of $286,655.60. Following the completion of the sale, the senior vice president directly owned 40,160 shares of the company’s stock, valued at approximately $1,002,795.20. The trade was a 22.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jean Holloway sold 977 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the transaction, the senior vice president owned 184,118 shares of the company’s stock, valued at approximately $5,245,521.82. The trade was a 0.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 90,460 shares of company stock worth $2,557,366. 6.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Artivion

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Artivion during the 2nd quarter worth about $149,965,000. Conestoga Capital Advisors LLC acquired a new position in shares of Artivion during the 1st quarter worth about $43,044,000. Bank of America Corp DE acquired a new position in shares of Artivion during the 2nd quarter worth about $11,717,000. Legal & General Group Plc acquired a new position in shares of Artivion during the 2nd quarter worth about $5,826,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Artivion during the 2nd quarter worth about $5,671,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a medical device company focused on products and services for cardiac and vascular surgery. The company develops, manufactures and distributes implantable devices, surgical adhesives and preserved human tissues used in the treatment of complex cardiovascular conditions.

Its product portfolio includes On-X mechanical heart valves and related repair technologies, BioGlue surgical adhesive, aortic stent grafts and other devices for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in surgical procedures.

The company was formerly known as CryoLife, Inc and adopted the Artivion name in 2021 to reflect its broader focus on cardiovascular and aortic therapies.